Innoviva, Inc. (INVA): Price and Financial Metrics

Innoviva, Inc. (INVA): $16.07

0.15 (-0.92%)

POWR Rating

Component Grades








Add INVA to Watchlist
Sign Up

Industry: Biotech




#18 of 348

in industry

INVA Price/Volume Stats

Current price $16.07 52-week high $16.86
Prev. close $16.22 52-week low $12.22
Day low $16.04 Volume 1,681,200
Day high $16.35 Avg. volume 623,848
50-day MA $15.54 Dividend yield N/A
200-day MA $14.81 Market Cap 1.00B

INVA Stock Price Chart Interactive Chart >

Innoviva, Inc. (INVA) Company Bio

Innoviva is a biopharmaceutical company. The Company develops small molecule medicines for respiratory disease, bacterial infections, and gastrointestinal disorders. The company was founded in 1996 and is based in South San Francisco, California.

INVA Latest News Stream

Event/Time News Detail
Loading, please wait...

INVA Latest Social Stream

Loading social stream, please wait...

View Full INVA Social Stream

Latest INVA News From Around the Web

Below are the latest news stories about INNOVIVA INC that investors may wish to consider to help them evaluate INVA as an investment opportunity.

Insider Sell Alert: Marianne Zhen Offloads Shares of Innoviva Inc

In the realm of stock market movements, insider trading activity is often a significant indicator that investors keep a close eye on.

Yahoo | November 18, 2023

Innoviva, Inc. (NASDAQ:INVA) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Most readers would already know that Innoviva's (NASDAQ:INVA) stock increased by 2.5% over the past month. However, the...

Yahoo | November 14, 2023

Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 Million

Despite a decrease in net income, the company shows promise with the launch of new therapy and positive Phase 3 data

Yahoo | November 3, 2023

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

BURLINGAME, Calif., November 01, 2023--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.

Yahoo | November 1, 2023

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

GENEVA & WALTHAM, Mass., November 01, 2023--The Global Antibiotic Research & Development Partnership (GARDP), in collaboration with Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today that zoliflodacin, a first-in-class antibiotic, met its primary endpoint in an unprecedented global pivotal Phase 3 clinical trial. Study investigators found that oral zoliflodacin demonstrated statistical non-inferiority of microbiological cure at the urogenital site whe

Yahoo | November 1, 2023

Read More 'INVA' Stories Here

INVA Price Returns

1-mo -0.50%
3-mo 6.49%
6-mo -0.92%
1-year 24.67%
3-year 19.75%
5-year 13.17%
YTD 0.19%
2023 21.06%
2022 -23.19%
2021 39.23%
2020 -12.50%
2019 -18.85%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!